How to survive the survival plots [11]

Lancet

Volumn 360, Issue 9337, 2002, Pages 954-

  De Lemos, Mário L ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; EVIDENCE BASED MEDICINE; FOLLOW UP; HAZARD ASSESSMENT; LETTER; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

EID: 0037152084     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11063-4     Document Type: Letter

References (5)

1. Pocock S.J., Clayton T.C., Altman D.G. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 359:2002;1686-1689.
2. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 35:1977;1-39.
3. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717.
4. Altman D.G., Andersen P.K. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 319:1999;1492-1495.
5. New drugs, V: Spironolactone (Aldactone®). In: Anon. Therapeutics letter, 34. Vancouver: University of British Columbia, 2000.